<DOC>
	<DOCNO>NCT01356537</DOCNO>
	<brief_summary>The purpose study proof increase patient satisfaction preservation quality life patient Gaucher 's Disease receive enzyme replacement therapy VPRIV ( Velaglucerase alfa ) home setting compare receive infusion clinic doctor 's practice .</brief_summary>
	<brief_title>Home Therapy With VPRIV Gaucher 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Male female patient confirm diagnosis Gaucher disease type 1 Age &gt; 2 year patient least 3 infusion ( 6 week ) least 5year 56 infusion ( 1012 week ) 2 4year patient receive VPRIV ® tolerate well The patient compliant , previous VPRIV ® infusion / perform approximately every 2 week center office visit The patient already inclusion study home infusion therapy consent ( legal representative ) The patient / lawful . Representative consent write participate study . Exclusion criterion : • The patient participate clinical trial medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>